ACRV
ACRIVON THERAPEUTICS INC

1,180
Mkt Cap
$51.12M
Volume
363,287.00
52W High
$6.08
52W Low
$1.05
PE Ratio
-0.76
ACRV Fundamentals
Price
$1.62
Prev Close
$1.62
Open
$1.62
50D MA
$2.17
Beta
1.60
Avg. Volume
3.69M
EPS (Annual)
-$2.38
P/B
0.40
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Increase in Short Interest
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totaling 7,521,144 shares, a...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the company, MarketBeat.com...
MarketBeat·11d ago
News Placeholder
Adam Levy Acquires 8,832 Shares of Acrivon Therapeutics (NASDAQ:ACRV) Stock
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CFO Adam Levy bought 8,832 shares of the company's stock in a transaction on Wednesday, January 14th. The shares were acquired at an average...
MarketBeat·24d ago
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) CFO Adam Levy Acquires 8,832 Shares
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CFO Adam Levy bought 8,832 shares of the firm's stock in a transaction on Wednesday, January 14th. The stock was bought at an average price...
MarketBeat·25d ago
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) CEO Peter Blume-Jensen Purchases 49,000 Shares
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CEO Peter Blume-Jensen purchased 49,000 shares of the company's stock in a transaction that occurred on Wednesday, January 14th. The shares...
MarketBeat·25d ago
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) COO Eric Devroe Purchases 10,000 Shares
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) COO Eric Devroe acquired 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 13th. The shares were...
MarketBeat·25d ago
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) COO Purchases $17,200.00 in Stock
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) COO Eric Devroe bought 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 13th. The shares were...
MarketBeat·26d ago
News Placeholder
Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data
(RTTNews) - Acrivon Therapeutics, Inc. (ACRV) shares fell 28.71%, trading at $2.1044, down $0.8456, after the company reported updated Phase 2b clinical results for its lead candidate ACR-368 in...
Nasdaq News: Markets·1mo ago
News Placeholder
Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls
Acrivon Therapeutics shares new trial data showing strong cancer responses, early tumor shrinkage, and pipeline progress, while confirming cash runway into 2027.read more...
Benzinga·1mo ago
News Placeholder
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan
Acrivon Therapeutics (NASDAQ:ACRV) highlighted new interim clinical results for its lead program ACR368 in endometrial cancer and provided early clinical and preclinical updates across its pipeline...
MarketBeat·1mo ago
<
1
2
...
>

Latest ACRV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.